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before transplantation in FAP and non-FAP patients. Mental component improved
in non-FAP (18.47) and worsened in FAP (-7.8) after transplantation. Physical com-
ponent showed improvement in both groups, but significantly greater in non-FAP
group (8.00 versus 16.76). Worst HRQoL scores were associated to limbs pain, dis-
ability, and mental symptoms. LTx must be performed early, before the onset of
somatic symptoms to improve chances of a better HRQoL. CONCLUSIONS: FAP
patients submitted to LTx present worse HRQoL scores when compared to non-FAP
transplanted patients. After LTx, FAP present worse mental component; physical
component showed improvement, but significantly lower than non-FAP group.
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OBJECTIVES: Familial amyloid polyneuropathy (FAP) is an autosomal dominant
disorder, caused by mutant transthyretin protein (TTR). Because most TTR is pro-
duced in hepatocytes, liver transplantation (LTx) has been a treatment option to
prevent long term disease progression. This study aims to report demographic and
clinical characteristics of FAP patients submitted to LTx in Brazil compared to FAP
World Transplant Registry (FAPWTR). METHODS: A literature review was per-
formed by May 2012 through Cochrane Collaboration, Medline, EMBASE, and Lilacs
databases. A retrospective analysis of epidemiological data available from FAPWTR
was developed from 1995 to 2010. RESULTS: From 1995 to 2010, 1,893 LTx were
recorded in 73 centers of 19 countries by FAPWTR. Of these, 5% were performed in
4 Brazilian centers. In FAPWRT cohort, 56% were male, median age at time of
transplantation was 38 years (21-72), and the median disease duration before LTx
was 3 years (0-30). The main causes of death were cardiac complications (22%),
sepsis (22%), liver related complications (14%) and perioperative complications
(3%). The 5-year survival rate was 82%. In a cohort from São Paulo University-Brazil,
24 patients underwent LTx. Patients characteristics were similar to FAPWRT (66.6%
male; median age 36 years), except for disease duration before transplantation
(median: 8 years [2-17]). Six deaths were registered and the main causes were
sepsis and hepatic artery thrombosis. Cardiac related deaths was also observed but
in one case. The overall 5-year survival rate was 58%. Data from 59 Brazilian sub-
jects enrolled in Transthyretin Amyloidosis Outcomes Survey (THAOS) indicated
81% of symptomatic patients and LTx performed in 37.5%. CONCLUSIONS: When
compared to FAPWTR, Brazilian cohort showed longer disease duration before LTx,
and a shorter 5-year survival rate after the procedure. This might be indicative of a
need for better diagnose and management of FAP patients in Brazil.
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OBJECTIVES: Liver transplantation (LTx) is a complex surgical procedure indicated
for patients with serious acute or chronic diseases, when no other effective treat-
ment is available. This retrospective study aims to report temporal trends and
geographic distribution of LTx in Brazil. METHODS: A systematic review was per-
formed by May 2012 to identify publications on LTx in Brazil through Cochrane
Collaboration, Medline, EMBASE, Lilacs databases and gray literature. A retrospec-
tive analysis of epidemiological data available from Brazilian Registry of Trans-
plants (Brazilian Association of Organ Transplants) and Report of Latin American
Transplantation (The Transplantation Society of Latin American and The Carib-
bean) was developed from 1985 to 2011. RESULTS: In Brazil, an increase in LTx
performed annually was observed since the first successful experience (1985). In
2011 1,492 LTx were performed, an increase of 496% over 5 procedures in 1985, with
a survival rate of 74% for patients and 70% for graft. Living donor procedures
showed an increase from 1995 to 2005, but a reduction after 2006 (5 in 1995; 192 in
2005; 104 in 2011). Deceased donor procedures present a continuous growth ten-
dency (3 in 1985; 1,388 in 2011). Nevertheless, in 2009, the waiting list had 4,850
registered patients. Geographic distribution is influenced by transplantation cen-
ters distribution. The distribution of [inhabitants; LTx centers; LTx procedures] in 5
Brazilian geographic region in 2011 is: North [8.09%; 0%; 0%], Northeast [27.97%;
15.79%; 21.24%], Midwest [7.32%; 2.63%; 0%], Southeast [42.20%; 60.53%; 57.92%],
and South [14.43%; 21.05%; 20.84%]. São Paulo state, placed in Southeast region,
represents 31 transplantation centers (76 in Brazil), 21.58% of country population
and 46% of LTx conducted in 2011. CONCLUSIONS: Brazil performed a growing
number of LTx from 1985 to 2011, but this increase may not be enough, once a large
patient’s number remains on waiting lists. Geographical distribution shows to be
significantly irregular in the country.
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OBJECTIVES: Recent recommendations (1) have underscored the need for anemia
assessment and treatment, including iron, prior to scheduled orthopedic surgery.
Administration of intravenous iron alone or combined to erythropoiesis stimulat-
ing agents (ESA) have also been shown to reduce transfusion requirements. How-
ever, the current practices are not well known. The aim of the present study was to
assess the management of iron supplementation and anemia in patients with
scheduled hip or knee surgery. METHODS: A total of 718 Anesthesiologists were
selected from a professional file. Their daily practice on anemia management was
evaluated through a questionnaire. RESULTS: The survey analysis was performed
on 117 questionnaires (return rate: 16%). The most frequent biological exams for
anemia and iron deficiency prescribed by surgeons (45%), anesthesiologist (48%) or
both (7%) before surgery were hemoglobin (100% of questionnaires), ferritin (35%),
serum iron (33%), transferrin and Transferrin saturation (24%). Among the 117
anesthesiologists, 94 (80.3%) declared to prescribe ESA and 104 (89%) iron (oral, 29%;
intravenous, 17%; both, 50%) before surgery. The main reasons to choose intrave-
nous iron were combination to ESA (54%), short delay before surgery (43%), poor
tolerance of oral iron (37%) or poor intestinal absorption (27%); intravenous iron
was also used in the absence of ESA for 37%. In case of anemia after surgery,
intravenous iron given in the first 24 hours was prescribed by 80% of anesthesiol-
ogist. When patient returned home, 65% of survey responders prescribed oral iron.
CONCLUSIONS:This survey shows that optimization of Hemoglobin before surgery
with the use of ESA and iron is wide, but the exploration of anemia is infrequent,
despite recent recommendations. Prospective studies aimed to assess the impact
of intravenous iron alone or combined to ESA before elective orthopedic surgery are
necessary. Prospective studies aimed at better defining the place of iron are still
needed.
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OBJECTIVES: Using information collected from leading Turkish gynecologists, the
costs of different clinical practices of laparoscopic surgery (LS) for endometriosis
treatment were compared. METHODS: Top gynecologists from Turkey were inter-
viewed regarding the best practices to treat endometriosis, including hospitaliza-
tion, tests ordered pre- and post surgery, and the number of follow-up visits per
patient. Physicians’ views were split into two camps with a few opinions in the
middle. The diverging physician opinions were compared and using the physi-
cians’ recommended laparoscopy procedures, the cost of endometriosis treatment
was estimated using Social Security Institution data. RESULTS: The answers re-
garding hospitalization following laparoscopic surgery differed between “hospital-
ization for all patients” and “no hospitalization” after LS. The percentage of pa-
tients recommended for chest radiography and electrocardiogram (ECG) also
varied between 30% and 100%. The number of follow-up visits differed with sug-
gestions for both no and one follow-up visit. Using the interview results and the
assumption that 5% of Turkish women between ages 18 and 49 (N1,000,000) suffer
from endometriosis, the total cost of laparoscopic treatment was estimated for two
sets of recommendations: a) the physician does not hospitalize patients, suggests
chest radiography and ECG for 30% of patients, and does not follow-up with any of
the patients after LS, and b) the physician hospitalizes all patients for one night,
suggests chest radiography and ECG for 100% of patients, and follows-up with all
patients after LS. Depending on physicians’ preference of treatment procedures,
projected costs varied from 200.24, to 241.30. CONCLUSIONS: Different clinical
perspectives and practices of laparoscopic treatment for endometriosis affect cost
of therapy by as much as 41,06 per patient. When combined with the estimated 1
million endometriosis patients in Turkey, total cost differs 41,060,000. Developing
a standard procedure for LS may help lower aggregate costs and cost variation of
procedure.
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OBJECTIVES: Examine the association between degenerative disk disease (DDD)
and patient length of stay (LOS) and total payments among patients who under-
went lumbar fusion surgery. METHODS: Patients who underwent an anterior lum-
bar interbody fusion (ALIF), posterior lumbar fusion (PLF) or transforaminal or pos-
terior lumbar interbody fusion (T/PLIF) surgery over the time period from 2006 -
2009 in the Thomson Reuters MarketScanÒDatabases were identified. These pa-
tients were examined for evidence of degenerative disk disease (DDD). Multivariate
regressions were used to examine the association between DDD and LOS and total
payments, while controlling for patient age, sex, type of insurance coverage, and
type of procedure. RESULTS: Of the 28,647 patients who underwent lumbar fusion
surgery, 7,230 had an ALIF, 16,374 had a PLF, and 5,043 had a T/PLIF. 13,340 (46.57%)
of the sample had a comorbid diagnosis of DDD (ICD-9 code 722.6x, 722.51, 722.52).
However, the majority of these patients were also diagnosed with an additional
comorbid back problem - only 1,911 (6.67%) were diagnosed with stand alone
DDD. Compared to patients without DDD, patients who had DDD and no additional
comorbid back problem were found to have $5,557 lower total payments (P0.0001)
and 0.17 shorter LOS (P0.0001), after controlling for patient characteristics and
type of procedure. In contrast, patients with DDD and an additional comorbid back
diagnoses were found to have $4,876 higher total payments and 0.07 longer LOS
compared to patients without DDD. CONCLUSIONS: DDD is an uncommon sole
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clinical rational for lumbar fusion surgery. Patients who underwent a ALIF, PLF or
T/PLIF with stand-alone DDD had significantly lower total payments and signifi-
cantly shorter LOS, while patients with DDD and additional back diagnoses had
significantly higher total payments and longer LOS compared to patients who un-
derwent an ALIF, PLF, or T/PLIF without a comorbid diagnosis of DDD.
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OBJECTIVES: Compare resource utilization and medical charges among patients
who had an anterior lumbar interbody fusion (ALIF), posterior lumbar interbody
fusion (PLF), or transforaminal posterior lumbar interbody fusion (T-PLIF) and a
subsequent revision surgery to those without such a revision surgery. METHODS:
The MedStat MarketScan databases from 2006 - 2009 were utilized for this retro-
spective analysis. Patients were included if had a ALIF, PLF, or T-PLIF and had
continuous insurance coverage for 2 years post procedure. Revision patients were
then matched to non-revision patients at a 2:1 ratio based upon type of initial
procedure, year of birth, sex, and region of residence Medical payments and re-
source utilization were compared between the two cohorts using t-statistics for
continuous variable and chi-square statistics for categorical variables. RESULTS: In
the 2 years post procedure, patients with a subsequent revision were significantly
more likely to visit a physical therapist (92% v 62%; P0.0001), receive an epidural
steroid injection (58% v 47%; P0.0074), or visit the emergency room with a diag-
nosis of back pain (20% v 9%; P0.0001). The average cost the initial surgery was
similar among the two cohorts ($39,925 v $38,341; P0.6422) while the mean cost
associated with a revision surgery was $35,296 (std dev$32,814). Total payments
for the two cohorts, ignoring the cost of the initial procedure was $33,180 for pa-
tients who did not have a subsequent revision, and $89,770 for patients with a
subsequent revision (P0.0001). These differences translate into a $56,590 cost
premium associated with a revision surgery – 62% of which can be accounted by the
revision surgery itself. CONCLUSIONS: Revision surgery was associated with sig-
nificantly more resource utilization post initial surgery. Comparing costs among
the two groups reveal a significant cost premium associated with revision surgery
and that such costs extended beyond the cost of the revision surgery itself.
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OBJECTIVES: Tuberous sclerosis complex (TSC) is a rare genetic disorder charac-
terized by benign tumor growth in multiple organs. TSC’s subsequent and varied
impacts on patients are typically treated by many different types of procedures.
This study aimed to assess the principal clinical manifestations imposed by the
disease and consequent major types of health care resource utilization experi-
enced among TSC patients in the United States (US). METHODS: An Institutional
Review Board-approved Internet-based survey of US TSC patients and caregivers
solicited information on prevalence of manifestations, disease management, and
impact on patients. Descriptive statistics were calculated. RESULTS: Of the 380
initial respondents, 53% were patients and 47% were caregivers. Surveys provided
data on 380 patients, of whom 59% were female and the mean age was 30.4 years
(SD: 17.3; median: 32.5). The majority of patients reported experiencing skin lesions
(53%) while seizures, cognitive concerns, cerebral tumors, angiomyolipomas (AML),
and subependymal giant cell astrocytomas (SEGA) were reported by 46%, 36%, 26%,
23%, and 21%, respectively. Ninety patients (24%) reported only one manifestation
of TSC, while 18%, 14%, and 38% reported 2, 3, or 4 or more. Over half of patients
(52%) had some type of TSC-related surgery including but not limited to brain
surgery (33%), embolization (12%), nephrectomy (7%), kidney transplant (6%), and
laser surgery (12%). Patients with SEGAs reported the highest level of brain surgery
(55%). Among patients with AMLs, embolization for kidney lesions (28%), nephrec-
tomy (12%) and kidney transplant (8%) were reported. CONCLUSIONS: In this anal-
ysis of initial respondents, TSC presents significant, and varied, epidemiological
and clinical burden in the US. Patients with SEGA and AMLs seemed to experience
the highest rates of invasive procedures among all patients with TSC.
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OBJECTIVES: The number of performed heart transplantations per year are well
published and can easily be accessed. Nevertheless, there are no exact figures on
the prevalence and incidence of patient survival after heart transplantation in
Germany, although these patients have high health care needs. Purpose of this
study was to generate these missing figures for the past and present as well as
taking an outlook into the future development until 2030. METHODS: Primarily
based on statistics from the Federal Statistical Office and liver transplant quality
reports of the German AQUA-Institute, relevant parameters and data were identi-
fied and used to develop an epidemiological model. Key drivers of the model are
yearly patient survival rates as well as growth rates of performed liver transplan-
tations. The model starts in 1987 and is able to predict the future development of
the cumulative liver transplant patient population until the year 2030. To account
for uncertainty, a 1.000 replication Monte-Carlo-Simulation with random samples
within published ranges of the input parameters was run. RESULTS: According to
our model currently (2012) about 7.773 (95% Confidence interval: 7.701 – 7.844)
patients with prior liver transplantation live in Germany. Until 2030 the model
estimates an increase of the population size to 17.490 (95% CI: 17.105 – 17.875)
people. The number of performed liver transplantations is estimated at 3.068 (95%
CI: 2.988 – 3.148) in 2030. CONCLUSIONS:With current assumptions the liver trans-
plant patient population size will continuously grow. The growth of this population
will primarily be limited by available organs for transplantation.
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OBJECTIVES: The number of performed heart transplantations per year are well pub-
lished and can easily be accessed. Nevertheless, there are no exact figures on the preva-
lence and incidence of patient survival after heart transplantation in Germany, although
these patients have high health care needs. Purpose of this study was to generate these
missing figures for the past and present as well as taking an outlook into the future de-
velopment until 2030.METHODS: Primarily based on statistics from the Federal Sta-
tistical Office and heart transplant quality reports of the German AQUA-Institute
relevant parameters and data were identified and used to develop an epidemiolog-
ical model. Key drivers of the model are yearly patient survival rates as well as
growth rates of performed heart transplantations. The model starts in 1980 and is
able to predict the future development of the cumulative heart transplant patient
population until the year 2030. To account for uncertainty, a 1.000 replication Mon-
te-Carlo-Simulation with random samples within published ranges of the input
parameters was run. RESULTS:According to our model currently (2012) about 4.072
(95% Confidence interval: 4.028 – 4.116) patients with prior heart transplantation
live in Germany. Until 2030 the model estimates a decrease of the population to
3.028 (95% CI: 2.980 – 3.077) people. Peak number of patients after heart transplan-
tation was estimated at 2007: 4.225 (95% CI: 4.192 – 4.257). The number of performed
heart transplantations is estimated at 266 (95% CI: 261-271) in 2030.CONCLUSIONS:
Even though the peak number of patients with heart transplants according to our
model has occurred in the past, still a considerable heart transplant patient popu-
lation is living at Germany and seeking health care services for their needs.
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INTRODUCTION: Evidence based medicine (EBM) is frequently used as the basis for
clinical guidelines and reimbursement recommendations. The hierarchy of evi-
dence is: Level I - randomized controlled trials (RCTs); Level II - nonrandomized
cohort studies; Level III - case control studies, Level IV - case series, and Level V -
expert opinion. RCTs are generally required when developing clinical guidelines or
reimbursement recommendations for drugs.OBJECTIVES:The purpose of this case
review is to illustrate an application of EBM to an innovative surgical procedure and
highlight how the recommendations for use changed with new evidence.
METHODS: NICE guidelines for arthroscopic surgery for femoro-acetabular im-
pingement were reviewed. This case study was selected because the treatment
modality represents a new surgical technology in which guidelines for coverage
recommendations, first promulgated in 2007, were later changed in 2011, illustrat-
ing the impact of additional evidence generation. RESULTS: In 2007, efficacy evi-
dence considered by NICE were two case series, with 158 and 10 patients respec-
tively. In 2011, efficacy evidence considered by NICE covered 1126 patients from 3
non-randomized controlled studies (none compared with natural history or non-
arthroscopic surgical techniques), 5 case series (with 100 to 200 hips), and 1 case
report. Twenty-two smaller case series were also identified. In 2011, four out of five
specialist advisors viewed the procedure as established while one advisor consid-
ered the efficacy and safety still to be uncertain. In 2007, NICE concluded “current
evidence . . . does not appear adequate for this procedure to be used without special
arrangements for consent and for audit or research” while in 2011 NICE concluded
“current evidence. . ... is adequate in terms of symptom relief in the short and
medium term.” CONCLUSIONS: For innovative surgical procedures in the UK, non-
randomized controlled studies and case series, supported by specialist recommen-
dation, may be sufficient for a positive recommendation by NICE.
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